FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average I	hurden										

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Arbuckle Stuart A</u>				2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								ionship of Reportin all applicable) Director Officer (give title	10%	Ssuer Owner (specify	
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED					3. Date of Earliest Transaction (Month/Day/Year) 09/19/2014							below) EVP\Chief Cor	belov	v)`	
50 NORTHERN AVENUE (Street)				4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
BOSTON	MA	02210										Form filed by Mor Person	e than One Re	porting	
(City)	(State)	(Zip)													
		Table I - No	n-Deriva	tive S	ecurities Acq	uired,	Disp	posed of, c	r Ben	eficial	ly C	Owned			
1. Title of Security (Instr. 3) 2. Trans Date (Month/				action ZA. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities ADISPOSED OF (5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

M

M

S⁽¹⁾

27,000

25,500

55.521

\$53.74

\$45.11

\$100

84,702

110,202

54,681

140

D

D

D

Ι

401(k)

A

Α

D

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$53.74	09/19/2014		М			27,000	(2)	09/03/2022	Common Stock	27,000	\$0.00	45,500	D	
Stock Option (right to buy)	\$45.11	09/19/2014		M			25,500	(3)	02/04/2023	Common Stock	25,500	\$0.00	65,125	D	

Explanation of Responses:

Common Stock

Common Stock

Common Stock

Common Stock

- 1. Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- 2. The option vests in 16 quarterly installments from 09/04/2012.
- 3. The option vests in 16 quarterly installments from 02/05/2013.

Remarks:

Kenneth L. Horton, Attorney-In-Fact

09/23/2014

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

09/19/2014

09/19/2014

09/19/2014

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.